We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.32, which matched the Zacks Consensus Estimate. STE beat on earnings in two of the trailing four quarters and met expectations twice, delivering an average surprise of 0.61%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).
Q4 Estimates for STE
The Zacks Consensus Estimate for revenues is pegged at $1.48 billion, suggesting an increase of 4.2% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pegged at $2.58, indicating a year-over-year increase of 7.1%.
Estimate Revision Trend Ahead of STE's Q4 Earnings
Estimates for earnings have remained constant at $2.58 per share in the past 60 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Healthcare
In the fiscal fourth quarter, growth across consumables and services was robust, favored by procedure volumes in the United States as well as price and market share gains. We expect this trend to have continued in the fiscal fourth quarter as well.
During the fiscal third-quarter earnings call, the tightened FY25 revenue growth guidance was attributed to lower-than-expected healthcare capital equipment revenues. The company, however, maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the fourth-quarter results. In the to-be-reported quarter, within Healthcare capital equipment, order growth is expected to remain robust despite ongoing shipment issues due to customer project delays.
Our model projects the segment’s revenues to improve 4.1% from the year-ago reported figure.
In the fiscal fourth quarter, Steris is expected to have experienced organic revenue growth within this segment. Also, AST’s performance during the last reported quarter was strong despite a decline in capital equipment shipments. In line with this, global MedTech customers are once again expected to have remained stable in the fourth quarter and the company is expected to have experienced an increase in bioprocessing demand. We expect these trends to have contributed to the to-be-reported quarter’s top line.
Per our model, AST segment’s revenues for the quarter are likely to increase 9% year over year.
Life Sciences
The segment's fiscal third-quarter reported revenues declined year over year as strong growth in consumables and services was offset by a decline in capital equipment revenue. This trend might have continued in the to-be-reported quarter. However, the segment’s margin is expected to have benefited from favorable mix and pricing in the to-be-reported quarter.
Our model projects the segment’s revenues to decline 1.5% year over year.
What Our Model Suggests for STE
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating on earnings, which is not the case here.
Earnings ESP: STERIS has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Premier (PINC - Free Report) has an Earnings ESP of +13.82% and a Zacks Rank #2 at present.
PINC’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 20.43%. The Zacks Consensus Estimate for third-quarter fiscal 2025 EPS implies a decline of 43.6% from the year-ago reported figure. You can see the complete list of today’s Zacks #1 Rank stocks here.
HealthEquity (HQY - Free Report) has an Earnings ESP of +2.03% and a Zacks Rank #3 at present.
HQY’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 12.78%. The Zacks Consensus Estimate for first-quarter fiscal 2026 EPS implies an improvement of 1.3% from the year-ago reported figure.
Progyny (PGNY - Free Report) has an Earnings ESP of +2.68% and a Zacks Rank #3 at present. The company is scheduled to release first-quarter results on May 8.
PGNY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 54.91%. The Zacks Consensus Estimate for first-quarter 2025 EPS implies an improvement of 15.4% from the year-ago reported figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Applied Sterilization Growth Help STE Beat Q4 Earnings Estimates?
STERIS plc (STE - Free Report) is scheduled to release fourth-quarter fiscal 2025 results on May 14, after market close.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.32, which matched the Zacks Consensus Estimate. STE beat on earnings in two of the trailing four quarters and met expectations twice, delivering an average surprise of 0.61%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).
Q4 Estimates for STE
The Zacks Consensus Estimate for revenues is pegged at $1.48 billion, suggesting an increase of 4.2% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pegged at $2.58, indicating a year-over-year increase of 7.1%.
Estimate Revision Trend Ahead of STE's Q4 Earnings
Estimates for earnings have remained constant at $2.58 per share in the past 60 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Healthcare
In the fiscal fourth quarter, growth across consumables and services was robust, favored by procedure volumes in the United States as well as price and market share gains. We expect this trend to have continued in the fiscal fourth quarter as well.
During the fiscal third-quarter earnings call, the tightened FY25 revenue growth guidance was attributed to lower-than-expected healthcare capital equipment revenues. The company, however, maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the fourth-quarter results. In the to-be-reported quarter, within Healthcare capital equipment, order growth is expected to remain robust despite ongoing shipment issues due to customer project delays.
Our model projects the segment’s revenues to improve 4.1% from the year-ago reported figure.
STERIS plc Price and EPS Surprise
STERIS plc price-eps-surprise | STERIS plc Quote
Applied Sterilization Technologies (AST)
In the fiscal fourth quarter, Steris is expected to have experienced organic revenue growth within this segment. Also, AST’s performance during the last reported quarter was strong despite a decline in capital equipment shipments. In line with this, global MedTech customers are once again expected to have remained stable in the fourth quarter and the company is expected to have experienced an increase in bioprocessing demand. We expect these trends to have contributed to the to-be-reported quarter’s top line.
Per our model, AST segment’s revenues for the quarter are likely to increase 9% year over year.
Life Sciences
The segment's fiscal third-quarter reported revenues declined year over year as strong growth in consumables and services was offset by a decline in capital equipment revenue. This trend might have continued in the to-be-reported quarter. However, the segment’s margin is expected to have benefited from favorable mix and pricing in the to-be-reported quarter.
Our model projects the segment’s revenues to decline 1.5% year over year.
What Our Model Suggests for STE
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating on earnings, which is not the case here.
Earnings ESP: STERIS has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Premier (PINC - Free Report) has an Earnings ESP of +13.82% and a Zacks Rank #2 at present.
PINC’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 20.43%. The Zacks Consensus Estimate for third-quarter fiscal 2025 EPS implies a decline of 43.6% from the year-ago reported figure. You can see the complete list of today’s Zacks #1 Rank stocks here.
HealthEquity (HQY - Free Report) has an Earnings ESP of +2.03% and a Zacks Rank #3 at present.
HQY’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 12.78%. The Zacks Consensus Estimate for first-quarter fiscal 2026 EPS implies an improvement of 1.3% from the year-ago reported figure.
Progyny (PGNY - Free Report) has an Earnings ESP of +2.68% and a Zacks Rank #3 at present. The company is scheduled to release first-quarter results on May 8.
PGNY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 54.91%. The Zacks Consensus Estimate for first-quarter 2025 EPS implies an improvement of 15.4% from the year-ago reported figure.